An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE (EPIK-OLE)
An Open-Label Extension of the Study XEN496 in Children With KCNQ2 Developmental and Epileptic Encephalopathy
Sponsor: Xenon Pharmaceuticals Inc.
Terminated
Sponsor decision; not a safety decision
Other terminated trials from Xenon Pharmaceuticals Inc.
More terminations from Xenon Pharmaceuticals Inc.
Other Brain Diseases trials with similar outcome
Listed as NCT04912856, this PHASE3 trial focuses on Brain Diseases and Central Nervous System Diseases and remains terminated or withdrawn. Sponsored by Xenon Pharmaceuticals Inc., it has been updated 9 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Mar 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Mar 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2024 — Jul 2024 [monthly]
Terminated PHASE3
Status: Active Not Recruiting → Terminated
-
Jul 2023 — Jan 2024 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
▶ Show 4 earlier versions
-
Dec 2022 — Jul 2023 [monthly]
Recruiting PHASE3
-
Sep 2022 — Dec 2022 [monthly]
Recruiting PHASE3
-
Nov 2021 — Sep 2022 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Sep 2021 — Nov 2021 [monthly]
Not Yet Recruiting PHASE3
First recorded
Aug 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Xenon Pharmaceuticals Inc.
For direct contact, visit the study record on ClinicalTrials.gov .